Cargando…

Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G

BACKGROUND: In the JCOG1108/WJOG7312G trial, a combination (FLTAX) of 5‐fluorouracil (FU) /leucovorin (FL) and paclitaxel (PTX) did not show superiority in overall survival (OS) to FL in untreated patients with severe peritoneal metastasis of gastric cancer (GC‐SPM), some of whom received second‐lin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arai, Hiroyuki, Inoue, Eisuke, Yamaguchi, Kensei, Boku, Narikazu, Hara, Hiroki, Nishina, Tomohiro, Tsuda, Masahiro, Shitara, Kohei, Shinozaki, Katsunori, Nakamura, Shinichiro, Hyodo, Ichinosuke, Muro, Kei, Sasako, Mitsuru, Terashima, Masanori, Nakajima, Takako E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559492/ https://www.ncbi.nlm.nih.gov/pubmed/34655175 http://dx.doi.org/10.1002/cam4.4303

Ejemplares similares

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G
por: Shitara, Kohei, et al.
Publicado: (2016)

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)
por: Okamoto, W., et al.
Publicado: (2022)

Usefulness of an S-1 dosage formula: an exploratory analysis of randomized clinical trial (JCOG1001)
por: Kawakami, Takeshi, et al.
Publicado: (2022)

Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study
por: Hosokawa, Ayumu, et al.
Publicado: (2020)

Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study
por: Arai, Hiroyuki, et al.
Publicado: (2019)

Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604)
por: Tahara, Makoto, et al.
Publicado: (2015)

Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)
por: Takahashi, Naoki, et al.
Publicado: (2023)

A Phase II Trial of Combined Treatment of Endoscopic Mucosal Resection and Chemoradiotherapy for Clinical Stage I Esophageal Carcinoma: Japan Clinical Oncology Group Study JCOG0508
por: Kurokawa, Yukinori, et al.
Publicado: (2009)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors
por: Shitara, Kohei, et al.
Publicado: (2019)

Impact of COVID-19 on gastric cancer treatment in Japanese high-volume centers: a JCOG stomach cancer study group survey
por: Tokunaga, Masanori, et al.
Publicado: (2021)

1108. Evaluation of Vancomycin Dosing in Adolescents
por: Weaver, Ashley I, et al.
Publicado: (2021)

HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1)
por: Ri, Masaki, et al.
Publicado: (2021)

Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study
por: Yamaguchi, Kensei, et al.
Publicado: (2021)

The CDC42 effector protein MRCKβ autophosphorylates on Threonine 1108
por: Unbekandt, Mathieu, et al.
Publicado: (2019)

Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial
por: Kurokawa, Y, et al.
Publicado: (2016)

Randomized controlled phase III trial to investigate superiority of robot-assisted gastrectomy over laparoscopic gastrectomy for clinical stage T1-4aN0-3 gastric cancer patients (JCOG1907, MONA LISA study): a study protocol
por: Makuuchi, Rie, et al.
Publicado: (2023)

Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1)
por: Nakamura, Nobuhiko, et al.
Publicado: (2021)

Climatic and societal impacts of a “forgotten” cluster of volcanic eruptions in 1108-1110 CE
por: Guillet, Sébastien, et al.
Publicado: (2020)

Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer
por: Doi, Toshihiko, et al.
Publicado: (2010)

Fluoropyrimidine-induced cardiotoxicity
por: Deac, Andrada Larisa, et al.
Publicado: (2020)

Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1, an ancillary of JCOG0910
por: Shida, Dai, et al.
Publicado: (2023)

HER2-positive gastric cancer
por: Boku, Narikazu
Publicado: (2013)

Poor association between dihydropyrimidine dehydrogenase ( DPYD ) genotype and fluoropyrimidine‐induced toxicity in an Asian population
por: Kanai, Masashi, et al.
Publicado: (2022)

Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
por: Taniguchi, Hiroya, et al.
Publicado: (2020)

FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study)
por: Mishima, Hideyuki, et al.
Publicado: (2012)

Individualized Dosing of Fluoropyrimidine‐Based Chemotherapy to Prevent Severe Fluoropyrimidine‐Related Toxicity: What Are the Options?
por: Knikman, Jonathan E., et al.
Publicado: (2020)

An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)
por: Kawakami, Hisato, et al.
Publicado: (2021)

Determinación del calor de combustión de diferentes materiales, mediante la bomba calorimétrica PARR 1108. : /
por: Román Sánchez, Oscar Daniel
Publicado: (2009)

1108. Diagnostic Yield of the BioFire FilmArray Gastrointestinal Panel in Hospitalized Children at an Academic Children’s Center
por: Madigan, Theresa, et al.
Publicado: (2018)

Sex differences in the safety of S‐1 plus oxaliplatin and S‐1 plus cisplatin for patients with metastatic gastric cancer
por: Yamada, Yasuhide, et al.
Publicado: (2019)

Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines
por: Shiga, Taro, et al.
Publicado: (2020)

The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
por: Cucciniello, Linda, et al.
Publicado: (2022)

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
por: Punt, C.J.A., et al.
Publicado: (2023)

Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol
por: Osumi, Hiroki, et al.
Publicado: (2022)

Non-Randomized Confirmatory Trial of Laparoscopy-Assisted Total Gastrectomy and Proximal Gastrectomy with Nodal Dissection for Clinical Stage I Gastric Cancer: Japan Clinical Oncology Group Study JCOG1401
por: Kataoka, Kozo, et al.
Publicado: (2016)

Tu1108: INTERVAL CANCERS IN PATIENTS WITH HEREDITARY GASTROINTESTINAL SYNDROMES AFTER ONE YEAR OF THE SARS-COV-2 PANDEMIC
por: Barchi, Alberto, et al.
Publicado: (2022)

SG-APSIC1108: Implementation of infection prevention and control in Indonesian hospitals: Identification of strengths, gaps, and challenges in current practices
por: Supriadi, Indri Rooslamiati, et al.
Publicado: (2023)

A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study)
por: Moritani, Konosuke, et al.
Publicado: (2019)

ACT-25 CLINICAL TRIALS BY THE JCOG BRAIN TUMOR STUDY GROUP
por: Nishikawa, Ryo
Publicado: (2019)

Geriatric Research Policy: Japan Clinical Oncology Group (JCOG) policy
por: Mizutani, Tomonori, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7t7fohgtq6o9f8hp8d736omrfi